Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium
- Sponsor
- Ramathibodi Hospital
- Study ID
- NCT01288404
- Status
- Completed
Conditions
- Pterygium of the Conjunctiva and Cornea
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Interventions
- Fluorometholone — DRUGtopical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
- Bevacizumab — DRUGsubconjunctival bevacizumab 1.25 mg/0.05mL
- Bevacizumab — DRUGsubconjunctival bevacizumab 2.5 mg/0.1mL
- Bevacizumab — DRUGsubconjunctival bevacizumab 3.75 mg/0.15mL
Study Details
Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.
Key Dates
- First listed
- Feb 2, 2011
- Start date
- Jan 31, 2008
- Status verified
- Jan 2011
- Primary completion
- Sep 30, 2010
- Completion
- Nov 30, 2010
Study Design
- Enrollment
- 80 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Controltopical 0.1% fluorometholone eye drops
- Active Comparator: Bevacizumab group 1Bevacizumab 1.25 mg/0.05mL
- Active Comparator: Bevacizumab group 2Bevacizumab 2.5 mg/0.1mL
- Active Comparator: bevacizumab group 3bevacizumab 3.75 mg/0.15mL
Primary Outcome Measure
Severity of impending recurrent pterygium [ Time Frame: 3 months ]